ncRNA 介导的 LPCAT1 高表达与肝癌的不良预后和肿瘤免疫浸润相关。
ncRNA-Mediated High Expression of LPCAT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Liver Hepatocellular Carcinoma.
机构信息
Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, China.
College of Pharmacy, Xiangnan University, Chenzhou, China.
出版信息
J Immunol Res. 2022 May 16;2022:1584397. doi: 10.1155/2022/1584397. eCollection 2022.
PURPOSE
To investigate the expression of LPCAT1 in liver hepatocellular carcinoma (LIHC) and its relationship with prognosis and immune infiltration and predict its upstream nonencoding RNAs (ncRNAs).
METHOD
In this study, expression analysis and survival analysis for LPCAT1 in pan cancers were first performed by using The Cancer Genome Atlas (TCGA) data, which suggested that LPCAT1 might be a potential LIHC oncogene. Then, ncRNAs contributing to the overexpression of LPCAT1 were explored in starBase by a combination of expression analysis, correlation analysis, and survival analysis. Immune cell infiltration of LPCAT1 in LIHC was finally investigated via Tumor Immune Estimation Resource (TIMER).
RESULT
SNHG3 was observed to be the most promising upstream lncRNA for the hsa-miR-139-5p/LPCAT1 axis in LIHC. In addition, the LPCAT1 level was significantly positively associated with tumor immune cell infiltration, biomarkers of immune cells, and immune checkpoint expression in LIHC.
CONCLUSION
To summarize, the upregulation of LPCAT1 mediated by ncRNAs is associated with poor prognosis, immune infiltration, and immune checkpoint expression in LIHC.
目的
研究 LPCAT1 在肝肝细胞癌（LIHC）中的表达及其与预后和免疫浸润的关系，并预测其上游非编码 RNA（ncRNA）。
方法
本研究首先利用癌症基因组图谱（TCGA）数据对 LPCAT1 在泛癌中的表达进行分析和生存分析，提示 LPCAT1 可能是 LIHC 的潜在癌基因。然后，通过表达分析、相关性分析和生存分析相结合，在 starBase 中探索导致 LPCAT1 过表达的 ncRNA。最后，通过肿瘤免疫估计资源（TIMER）研究 LPCAT1 在 LIHC 中的免疫细胞浸润。
结果
在 LIHC 中，SNHG3 被观察到是 hsa-miR-139-5p/LPCAT1 轴最有前途的上游 lncRNA。此外，LPCAT1 水平与 LIHC 中的肿瘤免疫细胞浸润、免疫细胞标志物和免疫检查点表达显著正相关。
结论
总之，ncRNA 介导的 LPCAT1 上调与 LIHC 中的不良预后、免疫浸润和免疫检查点表达相关。
Zotero 插件